UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 221

Sortiert nach

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial

Annals of oncology, 2015-08, Vol.26 (8), p.1722-1728

2015

Link zum Volltext

Verfügbarkeit prüfen

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients

Annals of oncology, 2017-06, Vol.28 (6), p.1325-1332

2017

Link zum Volltext

Verfügbarkeit prüfen

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Annals of oncology, 2022-08, Vol.33 (8), p.750-768

2022

Link zum Volltext

Verfügbarkeit prüfen

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

Annals of oncology, 2017-06, Vol.28 (6), p.1294-1301

2017

Link zum Volltext

Verfügbarkeit prüfen

ctDNA to detect minimal residual disease in pancreatic cancer: moving into clinical trials

Annals of oncology, 2019-09, Vol.30 (9), p.1410-1413

2019

Link zum Volltext

Verfügbarkeit prüfen

Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?

Annals of oncology, 2018-05, Vol.29 (5), p.1083-1084

2018

Link zum Volltext

Verfügbarkeit prüfen

KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer

Annals of oncology, 2018-12, Vol.29 (12), p.2280-2282

2018

Link zum Volltext

Verfügbarkeit prüfen

High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer

Annals of oncology, 2023-12, Vol.34 (12), p.1187-1193

2023

Link zum Volltext

Verfügbarkeit prüfen

MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial

Annals of oncology, 2017-02, Vol.28 (2), p.344-353

2017

Link zum Volltext

Verfügbarkeit prüfen

Optimizing the use of EGFR antibodies across the continuum of care in mCRC: Effect of online education on clinician knowledge, competence and confidence

Annals of oncology, 2018-06, Vol.29, p.v80-v80

2018

Link zum Volltext

Verfügbarkeit prüfen

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer

British journal of cancer, 2016-11, Vol.115 (10), p.1223-1233

2016

Link zum Volltext

Verfügbarkeit prüfen

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

Annals of oncology, 2019-03, Vol.30 (3), p.439-446

2019

Link zum Volltext

Verfügbarkeit prüfen

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer

Annals of oncology, 2018-06, Vol.29, p.v109-v109

2018

Link zum Volltext

Verfügbarkeit prüfen

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

Annals of oncology, 2018-02, Vol.29 (2), p.439-444

2018

Link zum Volltext

Verfügbarkeit prüfen

In the literature: December 2021

ESMO open, 2022-02, Vol.7 (1), p.100352, Article 100352

2022

Link zum Volltext

Verfügbarkeit prüfen

SRC-S6 axis as a potential mechanism of resistance to anti HER2 treatment in gastric cancer (GC) cell lines

Annals of oncology, 2017-10, Vol.28, p.vii16-vii16

2017

Link zum Volltext

Verfügbarkeit prüfen

A multi-omic analysis for prospective patient stratification in localised colorectal cancer (CRC)

Annals of oncology, 2018-10, Vol.29, p.viii717-viii717

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii182

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer

Annals of oncology, 2012-03, Vol.23 (3), p.664-670

2012

Link zum Volltext

Verfügbarkeit prüfen

Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy

Annals of oncology, 2018-06, Vol.29, p.v102-v102

2018

Link zum Volltext

Verfügbarkeit prüfen

Identification of molecular mechanisms of acquired resistance to trastuzumab in gastric cancer

European journal of cancer (1990), 2016-07, Vol.61, p.S124-S125

2016

Link zum Volltext

Verfügbarkeit prüfen

Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

Endocrine-related cancer, 2006-06, Vol.13 (2), p.607-616

2006

Link zum Volltext

Verfügbarkeit prüfen

2161 The prognostic significance of radiologic and pathologic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-years update GEMCAD 0801 trial

European journal of cancer (1990), 2015-09, Vol.51, p.S387-S387

2015

Link zum Volltext

Verfügbarkeit prüfen

2051 Relation between RAS mutations and radiologic (RECIST and morphologic) and pathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study

European journal of cancer (1990), 2015-09, Vol.51, p.S345-S346

2015

Link zum Volltext

Verfügbarkeit prüfen

2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial

European journal of cancer (1990), 2015-09, Vol.51, p.S416-S416

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 221

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(195)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(69)
Humans
(60)
Life Sciences & Biomedicine
(59)
Female
(42)
Oncology
(29)
Adult
(27)
Male
(27)
Aged
(22)
Middle Aged
(21)
Biological And Medical Sciences
(17)
Medical Sciences
(16)
Animals
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Colorectal Cancer
(9)
Colorectal Neoplasms - Drug Therapy
(9)
Hematology
(9)
Antineoplastic Agents - Therapeutic Use
(8)
Mutation
(8)
Physical Sciences
(8)
Tumors
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

ctDNA to detect minimal residual disease in pancreatic cancer: moving into clinical trials

Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?

KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer

High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer

MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial

Optimizing the use of EGFR antibodies across the continuum of care in mCRC: Effect of online education on clinician knowledge, competence and confidence

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

In the literature: December 2021

SRC-S6 axis as a potential mechanism of resistance to anti HER2 treatment in gastric cancer (GC) cell lines

A multi-omic analysis for prospective patient stratification in localised colorectal cancer (CRC)

Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials

Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer

Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy

Identification of molecular mechanisms of acquired resistance to trastuzumab in gastric cancer

Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

2161 The prognostic significance of radiologic and pathologic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-years update GEMCAD 0801 trial

2051 Relation between RAS mutations and radiologic (RECIST and morphologic) and pathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study

2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial

Suchergebnisse filtern